Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E |
Therapy | Dabrafenib |
Indication/Tumor Type | gastrointestinal stromal tumor |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | gastrointestinal stromal tumor | predicted - sensitive | Dabrafenib | Case Reports/Case Series | Actionable | In a clinical case study, third-line treatment with Tafinlar (dabrafenib) resulted in a partial response lasting 19 months in a patient with gastrointestinal stromal tumor harboring BRAF V600E (PMID: 38756640). | 38756640 |
BRAF V600E | gastrointestinal stromal tumor | predicted - sensitive | Dabrafenib | Case Reports/Case Series | Actionable | In a clinical case study, Tafinlar (dabrafenib) treatment resulted in a 20% decrease in tumor size after 24 weeks in a patient with a gastrointestinal stromal tumor harboring BRAF V600E (PMID: 23470635). | 23470635 |
PubMed Id | Reference Title | Details |
---|---|---|
(23470635) | BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. | Full reference... |
(38756640) | Treatment of BRAF V600E mutant gastrointestinal stromal tumor with dabrafenib: a case report. | Full reference... |